Limited distribution drug contracts are among the most valuable in specialty pharmacy. They come with guaranteed patient volume, higher margins, and a defensible market position. They also come with a non-negotiable requirement: structured clinical data. Pharmacies that can't deliver it are competing on price in a market where margins are already razor thin.
Manufacturers want to know if their drug is working: persistence rates, discontinuation reasons, efficacy signals. Payers want outcomes to justify reimbursement. But all you can report is fill rates and adherence metrics. You have no structured way to measure clinical response over time, per disease state, specific to the therapy. Every LDD contract review is a negotiation you're entering without the data they're asking for.
Disease-specific scored assessments measure clinical response on a ±100 scale, with baseline plus longitudinal trending at defined intervals. You don't just know if the patient is taking the drug. You know if it's helping their MS, their IBS, their migraine, quantitatively. That data flows to pharma, payers, and your clinical team without anyone building a report. You show up to the contract review with outcomes data, not just fill rates.
This is the unlock for LDD contracts. Pharma demands structured data to justify limited distribution. Pharmacies that can deliver it win contracts. Pharmacies that can't are stuck competing on price, where margins are already razor thin.
All Insights